Moneycontrol
HomeNewsBusinessReal EstateGross office leasing across top 8 cities at 9.9 msf in Q2FY21
Trending Topics

Gross office leasing across top 8 cities at 9.9 msf in Q2FY21

Hyderabad recorded a 2X growth in gross leasing, both on q-o-q and y-o-y basis with the highest pre-commitments since Q3 2020 and major transaction closures

July 16, 2021 / 13:22 IST
Story continues below Advertisement
Office rentals remained stable across the major office markets in India in Q2 2021.

Gross leasing across top eight cities stood at 9.9 msf in Q2 2021, a 55 percent increase in gross leasing as compared to 6.39 msf gross leasing in Q2 2020, a report by Cushman & Wakefield has said.

Hyderabad, Delhi-NCR and Mumbai emerged as the most active office leasing markets in the quarter. Hyderabad recorded a 2X growth in gross leasing, both on quarter-on-quarter (QoQ) and year-on-year (YoY) basis with the highest pre-commitments since Q3 2020 and major transaction closures, it said.

Story continues below Advertisement

Delhi NCR’s gross leasing was 13.5 percent lower on a quarterly basis but more than double that of the leasing volume during the same period last year, the report said.

Market activity was driven by pre-commitments and term renewals even as fresh leasing remained relatively muted.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show